bioMerieux (OTCMKTS:BMXMF) Reaches New 12-Month Low – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as $77.00 and last traded at $78.00, with a volume of 1105 shares traded. The stock had previously closed at $78.16.

Analysts Set New Price Targets

BMXMF has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a report on Wednesday. UBS Group cut bioMerieux from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. Piper Sandler initiated coverage on bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating for the company. Finally, Zacks Research raised bioMerieux to a “hold” rating in a report on Tuesday, April 28th. Five equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, bioMerieux presently has an average rating of “Hold”.

bioMerieux Stock Down 0.2%

The business has a fifty day simple moving average of $89.39 and a 200-day simple moving average of $108.45. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.